OCA at 05:45, 4 September 2024

2024-09-04T05:45:32Z

← Older revision		Revision as of 05:45, 4 September 2024
Line 1:		Line 1:
	~~'''Unreleased structure'''~~

	The ~~entry 9eor~~ is ~~ON HOLD~~ ~~until Paper~~ Publication		==SARS-CoV2 major protease in complex with a covalent inhibitor SLL12.==
			<StructureSection load='9eor' size='340' side='right'caption='[[9eor]], [[Resolution\|resolution]] 2.25Å' scene=''>
			== Structural highlights ==
			<table><tr><td colspan='2'>[[9eor]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome_coronavirus_2 Severe acute respiratory syndrome coronavirus 2]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9EOR OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9EOR FirstGlance]. <br>
			</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.25Å</td></tr>
			<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9eor FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9eor OCA], [https://pdbe.org/9eor PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9eor RCSB], [https://www.ebi.ac.uk/pdbsum/9eor PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9eor ProSAT]</span></td></tr>
			</table>
			== Function ==
			[https://www.uniprot.org/uniprot/R1AB_SARS2 R1AB_SARS2] Multifunctional protein involved in the transcription and replication of viral RNAs. Contains the proteinases responsible for the cleavages of the polyprotein.[UniProtKB:P0C6X7] Inhibits host translation by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome complex further induces an endonucleolytic cleavage near the 5'UTR of host mRNAs, targeting them for degradation. Viral mRNAs are not susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the presence of a 5'-end leader sequence and are therefore protected from degradation. By suppressing host gene expression, nsp1 facilitates efficient viral gene expression in infected cells and evasion from host immune response.[UniProtKB:P0C6X7] May play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses.[UniProtKB:P0C6X7] Responsible for the cleavages located at the N-terminus of the replicase polyprotein. In addition, PL-PRO possesses a deubiquitinating/deISGylating activity and processes both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular substrates. Participates together with nsp4 in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication. Antagonizes innate immune induction of type I interferon by blocking the phosphorylation, dimerization and subsequent nuclear translocation of host IRF3. Prevents also host NF-kappa-B signaling.[UniProtKB:P0C6X7] Participates in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication.[UniProtKB:P0C6X7] Cleaves the C-terminus of replicase polyprotein at 11 sites. Recognizes substrates containing the core sequence [ILMVF]-Q-\|-[SGACN] (PubMed:32198291). Also able to bind an ADP-ribose-1''-phosphate (ADRP).[UniProtKB:P0C6X7]<ref>PMID:32198291</ref> Plays a role in the initial induction of autophagosomes from host reticulum endoplasmic. Later, limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes.[UniProtKB:P0C6X7] Forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.[UniProtKB:P0C6X7] Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers.[UniProtKB:P0C6X7] May participate in viral replication by acting as a ssRNA-binding protein.[UniProtKB:P0C6X7] Plays a pivotal role in viral transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16 2'-O-methyltransferase activities. Therefore plays an essential role in viral mRNAs cap methylation.[UniProtKB:P0C6X7] Responsible for replication and transcription of the viral RNA genome.[UniProtKB:P0C6X7] Multi-functional protein with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. Activity of helicase is dependent on magnesium.[UniProtKB:P0C6X7] Enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity. Acts as a proofreading exoribonuclease for RNA replication, thereby lowering The sensitivity of the virus to RNA mutagens.[UniProtKB:P0C6X7] Mn(2+)-dependent, uridylate-specific enzyme, which leaves 2'-3'-cyclic phosphates 5' to the cleaved bond.[UniProtKB:P0C6X7] Methyltransferase that mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of nsp16. Therefore plays an essential role in viral mRNAs cap methylation which is essential to evade immune system.[UniProtKB:P0C6X7]
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			In vitro screening of large compound libraries with automated high-throughput screening is expensive and time-consuming and requires dedicated infrastructures. Conversely, the selection of DNA-encoded chemical libraries (DECLs) can be rapidly performed with routine equipment available in most laboratories. In this study, we identified novel inhibitors of SARS-CoV-2 main protease (M(pro)) through the affinity-based selection of the DELopen library (open access for academics), containing 4.2 billion compounds. The identified inhibitors were peptide-like compounds containing an N-terminal electrophilic group able to form a covalent bond with the nucleophilic Cys145 of M(pro), as confirmed by x-ray crystallography. This DECL selection campaign enabled the discovery of the unoptimized compound SLL11 (IC(50) = 30 nM), proving that the rapid exploration of large chemical spaces enabled by DECL technology allows for the direct identification of potent inhibitors avoiding several rounds of iterative medicinal chemistry. As demonstrated further by x-ray crystallography, SLL11 was found to adopt a highly unique U-shaped binding conformation, which allows the N-terminal electrophilic group to loop back to the S1' subsite while the C-terminal amino acid sits in the S1 subsite. MP1, a close analog of SLL11, showed antiviral activity against SARS-CoV-2 in the low micromolar range when tested in Caco-2 and Calu-3 (EC(50) = 2.3 microM) cell lines. As peptide-like compounds can suffer from low cell permeability and metabolic stability, the cyclization of the compounds will be explored in the future to improve their antiviral activity.

	~~Authors: Moche~~, M., ~~Lennerstrand~~, J., Nyman, T., ~~Strandback~~, E., ~~Akaberi~~, D.		Identification of novel and potent inhibitors of SARS-CoV-2 main protease from DNA-encoded chemical libraries.,Akaberi D, Pourghasemi Lati M, Krambrich J, Berger J, Neilsen G, Strandback E, Turunen SP, Wannberg J, Gullberg H, Moche M, Chinthakindi PK, Nyman T, Sarafianos SG, Sandstrom A, Jarhult JD, Sandberg K, Lundkvist A, Verho O, Lennerstrand J Antimicrob Agents Chemother. 2024 Aug 28:e0090924. doi: 10.1128/aac.00909-24. PMID:39194208<ref>PMID:39194208</ref>

	~~Description: SARS-CoV2 major protease in complex with~~ a ~~covalent inhibitor SLL12~~.		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	[[Category: ~~Unreleased~~ Structures]]		</div>
	[[Category: ~~Moche, M~~]]		<div class="pdbe-citations 9eor" style="background-color:#fffaf0;"></div>
	[[Category: ~~Strandback, E~~]]		== References ==
	[[Category: Lennerstrand, J]]		<references/>
	[[Category: Nyman, T]]		__TOC__
	[[Category: ~~Akaberi, D~~]]		</StructureSection>
			[[Category: Large Structures]]
			[[Category: Severe acute respiratory syndrome coronavirus 2]]
			[[Category: Akaberi D]]
			[[Category: Lennerstrand J]]
			[[Category: Moche M]]
			[[Category: Nyman T]]
			[[Category: Strandback E]]

OCA at 15:13, 29 May 2024

2024-05-29T15:13:48Z

← Older revision		Revision as of 15:13, 29 May 2024
Line 7:		Line 7:
	Description: SARS-CoV2 major protease in complex with a covalent inhibitor SLL12.		Description: SARS-CoV2 major protease in complex with a covalent inhibitor SLL12.
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
			[[Category: Moche, M]]
	[[Category: Strandback, E]]		[[Category: Strandback, E]]
			[[Category: Lennerstrand, J]]
	[[Category: Nyman, T]]		[[Category: Nyman, T]]
	[[Category: Akaberi, D]]		[[Category: Akaberi, D]]
	~~[[Category: Lennerstrand, J]]~~
	~~[[Category: Moche, M]]~~

OCA at 07:07, 9 May 2024

2024-05-09T07:07:06Z

← Older revision		Revision as of 07:07, 9 May 2024
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 9eor is ON HOLD		The entry 9eor is ON HOLD until Paper Publication

	Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D.		Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D.

OCA: Protected "9eor" [edit=sysop:move=sysop]

2024-03-27T09:21:51Z

Protected "9eor" [edit=sysop:move=sysop]

← Older revision	Revision as of 09:21, 27 March 2024
(No difference)

OCA: New page: '''Unreleased structure''' The entry 9eor is ON HOLD Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D. Description: SARS-CoV2 major protease in complex with ...

2024-03-27T09:21:50Z

New page: '''Unreleased structure''' The entry 9eor is ON HOLD Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D. Description: SARS-CoV2 major protease in complex with ...

New page

'''Unreleased structure'''

The entry 9eor is ON HOLD

Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D.

Description: SARS-CoV2 major protease in complex with a covalent inhibitor SLL12.
[[Category: Unreleased Structures]]
[[Category: Strandback, E]]
[[Category: Nyman, T]]
[[Category: Akaberi, D]]
[[Category: Lennerstrand, J]]
[[Category: Moche, M]]

9eor - Revision history

OCA at 05:45, 4 September 2024

OCA at 15:13, 29 May 2024

OCA at 07:07, 9 May 2024

OCA: Protected "9eor" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 9eor is ON HOLD Authors: Moche, M., Lennerstrand, J., Nyman, T., Strandback, E., Akaberi, D. Description: SARS-CoV2 major protease in complex with ...